Skip to main content
Terug
DOCS logo

Doximity, Inc.

Datakwaliteit: 100%
DOCS
NYSE Healthcare Medical - Healthcare Information Services
€ 24,34
▼ € 0,69 (-2,76%)
Marktkapitalisatie: 4,57B
Dagbereik
€ 24,08 € 24,74
52-Weeksbereik
€ 23,53 € 76,51
Volume
2.389.965
50D / 200D Gem.
€ 31,02 / € 52,72
Vorige Slotkoers
€ 25,03

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 20,5 0,3
P/B 4,2 2,9
ROE % 22,5 3,7
Net Margin % 39,1 3,8
Rev Growth 5Y % 28,9 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 45,87 +88.5%
Low: € 25,00 High: € 81,00
Forward K/W
16,2
Forward WPA
€ 1,55
WPA Groei (sch.)
+0,0%
Omzet Sch.
640 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 2,41
€ 2,33 – € 2,52
 990 M 3
FY2029 € 1,95
€ 1,88 – € 2,04
 820 M 3
FY2028 € 1,80
€ 1,49 – € 2,27
 770 M 8

Belangrijkste Punten

Revenue grew 28,86% annually over 5 years — strong growth
Earnings grew 51,23% over the past year
ROE of 22,50% indicates high profitability
Net margin of 39,13% shows strong profitability
Debt/Equity of 0,01 — conservative balance sheet
Generating 266,74M in free cash flow

Groei

Revenue Growth (5Y)
28,86%
Revenue (1Y)19,98%
Earnings (1Y)51,23%
FCF Growth (3Y)24,02%

Kwaliteit

Return on Equity
22,50%
ROIC15,60%
Net Margin39,13%
Op. Margin39,94%

Veiligheid

Debt / Equity
0,01
Current Ratio6,97
Interest Coverage0,00

Waardering

P/E Ratio
20,49
P/B Ratio4,22
EV/EBITDA19,21
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19,98% Revenue Growth (3Y) 16,67%
Earnings Growth (1Y) 51,23% Earnings Growth (3Y) 40,65%
Revenue Growth (5Y) 28,86% Earnings Growth (5Y) 45,20%
Profitability
Revenue (TTM) 570,40M Net Income (TTM) 223,19M
ROE 22,50% ROA 17,65%
Gross Margin 90,20% Operating Margin 39,94%
Net Margin 39,13% Free Cash Flow (TTM) 266,74M
ROIC 15,60% FCF Growth (3Y) 24,02%
Safety
Debt / Equity 0,01 Current Ratio 6,97
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 20,49 P/B Ratio 4,22
P/S Ratio 8,02 PEG Ratio 0,92
EV/EBITDA 19,21 Dividend Yield 0,00%
Market Cap 4,57B Enterprise Value 4,38B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 570,40M 475,42M 419,05M 343,55M 206,90M
Net Income 223,19M 147,58M 112,82M 154,78M 50,21M
EPS (Diluted) 1,11 0,72 0,53 0,70 0,12
Gross Profit 514,53M 424,75M 365,56M 303,76M 175,70M
Operating Income 227,80M 163,88M 125,11M 113,54M 53,30M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,26B 1,08B 1,14B 991,36M 251,72M
Total Liabilities 181,68M 177,98M 170,77M 112,76M 184,98M
Shareholders' Equity 1,08B 901,40M 966,12M 878,59M 66,74M
Total Debt 12,40M 14,55M 15,64M 1,09M 1,25M
Cash & Equivalents 209,61M 96,79M 158,03M 112,81M 66,39M
Current Assets 1,09B 912,94M 975,45M 904,14M 209,40M
Current Liabilities 156,26M 147,25M 139,51M 111,28M 102,04M

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#965 of 1052
21
Custom Capital Light Compounder
#140 of 218
34
Growth Growth Investing (Philip Fisher)
#110 of 157
42
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#111 of 332
58
Value Value Investing (Warren Buffett)
#167 of 203
31
Custom Balanced Risk
#55 of 151
50
Custom Lower Risk
#112 of 140
36

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026